Current Report Filing (8-k)
2021年4月27日 - 7:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 9, 2021
GENETHERA,
INC.
(Exact
name of registrant as specified in its charter)
|
|
|
Nevada
|
000-27237
|
65-0622463
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
3051
W 105th Ave. Westminster, CO
|
|
80031
|
(Address of principal executive offices)
|
|
(Zip
Code)
|
Registrants
telephone number, including area code: (720) 587-5100
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions.
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM
1.01 GENETHERA, INC. AND CUMMING MANAGEMENT GROUP, INC. ENTERED INTO A CONSULTING AGREEMENT
On
April 9, 2021 GeneThera Inc. entered into a consulting agreement with Cumming Management Group, Inc. According to the terms on
the agreement, Cumming will provide support services related to the construction of GeneTheras Biosafety Level 3 (BSL-3)
laboratory facilities to be used as molecular robotic diagnostic therapeutic and research facilities for SARS-CoV-2 and other
zoonotic diseases. Scope of the services and fees are outlined in Exhibit A and B attached to the Consulting Agreement. GeneThera
will proceed with Cumming as its sole consulting services provider for the related BSL-3 Lab project.
Item
9.01 EXHIBITS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to
be signed on its behalf by the undersigned hereunto duly authorized.
|
GeneThera, Inc.,
|
|
a Nevada Corporation
|
|
|
|
By:/s/
Antonio Milici
|
|
Antonio Milici, CEO
|
Date:
April 27, 2021
GeneThera (CE) (USOTC:GTHR)
過去 株価チャート
から 11 2024 まで 12 2024
GeneThera (CE) (USOTC:GTHR)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about GeneThera Inc (CE) (その他OTC): 0 recent articles
その他のGenethera Incニュース記事